Skip to main content

Table 1 Baseline Characteristics of All Participants

From: The relationship between SARS-COV-2 RNA positive duration and the risk of recurrent positive

  Non-recurrent positive Recurrent positive P value
No. of patients 170 241  
Sex
 Female 81 (47.65%) 121 (50.21%) 0.609
 Male 89 (52.35%) 120 (49.79%)
Age, Median (IQR), year 47.00 (35.00–61.00) 50.00 (38.00–63.00) 0.023
BMI, Mean (SD), kg/m2 22.93 (3.24) 22.98 (4.35) 0.894
SPD, Median (IQR), day 16.50 (12.00–24.00) 20.00 (13.00–29.00) 0.020
Routine blood test
 WBC, Mean (SD), × 109/L 5.37 (1.89) 6.22 (2.69) < 0.001
 NC, Median (IQR), × 109/L 2.86 (2.15–3.91) 3.10 (2.36–4.18) 0.163
 NP, Mean (SD), % 58.69 (12.60) 54.90 (17.74) 0.017
 LC, Median (IQR), × 109/L 1.34 (1.00–1.80) 1.63 (1.24–2.12) < 0.001
 LP, Mean (SD), % 29.73 (11.86) 31.71 (14.66) 0.146
 MC, Median (IQR), × 109/L 0.49 (0.39–0.63) 0.43 (0.34–0.56) 0.005
 MP, Median (IQR), % 9.75 (7.53–12.50) 7.40 (6.10–9.40) < 0.001
 Hemoglobin, Mean (SD), g/L 130.98 (16.20) 128.03 (21.38) 0.130
 PLT, Mean (SD), × 109/L 203.06 (66.38) 219.19 (74.74) 0.025
Clinical type
 Mild 7 (4.12%) 22 (9.13%) 0.141
 Moderate 141 (82.94%) 179 (74.27%)
 Severe 17 (10.00%) 32 (13.28%)
 Critical 5 (2.94%) 8 (3.32%)
Underlying disease
 No. of chronic diseases
  0 123 (72.35%) 139 (57.68%) 0.002
  1 35 (20.59%) 65 (26.97%)
  2 12 (7.06%) 21 (8.71%)
  3 0 (0.00%) 12 (4.98%)
  4 0 (0.00%) 4 (1.66%)
 Hypertension
  No 144 (84.71%) 191 (79.25%) 0.161
  Yes 26 (15.29%) 50 (20.75%)
 Diabetes
  No 157 (92.35%) 218 (90.46%) 0.503
  Yes 13 (7.65%) 23 (9.54%)
 CHD
  No 166 (97.65%) 227 (94.19%) 0.092
  Yes 4 (2.35%) 14 (5.81%)
 CPD
  No 165 (97.06%) 225 (93.36%) 0.094
  Yes 5 (2.94%) 16 (6.64%)
 CKD
  No 168 (98.82%) 238 (98.76%) 0.95
  Yes 2 (1.18%) 3 (1.24%)
 CLD
  No 162 (95.29%) 203 (84.23%) < 0.001
  Yes 8 (4.71%) 38 (15.77%)
 Malignant tumor
  No 168 (98.82%) 236 (97.93%) 0.705
  Yes 2 (1.18%) 5 (2.07%)
Treatment
 No. of antiviral drugs
  0 32 (18.82%) 46 (19.09%) 0.001
  1 72 (42.35%) 106 (43.98%)
  2 47 (27.65%) 84 (34.85%)
  3 19 (11.18%) 5 (2.07%)
 Glucocorticoid
  No 143 (84.12%) 223 (92.53%) 0.007
  Yes 27 (15.88%) 18 (7.47%)
  1. Data presented as mean and standard deviation (Gaussian distribution, compared with student t-test) or median and quartile (Skewed distribution, compared with Kruskal–Wallis analysis) for continuous variables; number and percentage for categorical variables (Chi-square or Fisher’s exact tests)
  2. Clinical type, routine blood test and treatment were the conditions of previous discharge
  3. CPD included COPD, tuberculosis, asthma, and idiopathic pulmonary fibrosis. CLD included chronic hepatitis B, chronic hepatitis C, nonalcoholic steatohepatitis, autoimmune liver disease and cirrhosis. Antiviral drugs include Favipiravir, Oseltamivir, Chloroquine/Hydroxychloroquine, Lopinavir–Ritonavir, Remdesivir and Arbidol
  4. SD standard deviation, CHD coronary heart disease, CPD chronic pulmonary disease, CKD chronic kidney disease, CLD chronic liver disease, WBC white blood cell count, NC neutrophil count, NP neutrophil percentage, LC lymphocyte count, LP lymphocyte percentage, MC monocyte count, MP monocyte percentage, PLT platelet count, SPD SARS-CoV-2 RNA positive duration
\